Enhancement of radiotherapy with DNA topoisomerase I-targeted drugs

Allan Y. Chen, Rachel Chou, Shyh Jen Shih, Derick H Lau, David R Gandara

Research output: Contribution to journalArticlepeer-review

24 Scopus citations


Since its discovery more than a century ago, ionizing radiation has become a mainstay therapy for patients suffering from cancers. Currently, radiotherapy provides cure or palliative care for approximately one half of the cancer population. The anticancer efficacy of radiotherapy is, however, largely limited by its lack of tumor specificity and, consequently, normal tissue toxicity. There is an urgent need to develop systemic adjuncts that can enhance the efficacy and the selectivity of radiotherapy toward tumor cells. DNA topoisomerase I (TOP1)-targeted drugs such as camptothecin derivatives represent a novel class of chemotherapeutic agents that have recently been shown to be excellent radiation sensitizers. Combined modality therapy with TOP1-targeted drugs and radiotherapy represents a new promising cancer therapy. The mechanism of enhancement of radiotherapy by TOP1-targeted drugs is under intense investigation. Clinical trials using combinations of radiation and camptothecin derivatives are also currently ongoing in various solid tumors including brain, head and neck, and lung cancers. A better understanding of the radiosensitization (RS) mechanism of TOP1-targeted drugs is pivotal to their clinical application, as well as in guiding the development of better radiation sensitizers.

Original languageEnglish (US)
Pages (from-to)111-119
Number of pages9
JournalCritical Reviews in Oncology/Hematology
Issue number2
StatePublished - May 2004

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology


Dive into the research topics of 'Enhancement of radiotherapy with DNA topoisomerase I-targeted drugs'. Together they form a unique fingerprint.

Cite this